440 related articles for article (PubMed ID: 31272498)
21. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
Maksymowych WP; Inman RD; Bessette L; Rahman P; Rampakakis E; Asin-Milan O; Rachich M; Marrache AM; Lehman AJ
Arthritis Res Ther; 2023 Apr; 25(1):70. PubMed ID: 37118833
[TBL] [Abstract][Full Text] [Related]
22. Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis.
Park JW; Kwon HM; Park JK; Choi JY; Lee EB; Song YW; Lee EY
PLoS One; 2016; 11(12):e0168958. PubMed ID: 28033420
[TBL] [Abstract][Full Text] [Related]
23. Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis.
Micheroli R; Hebeisen M; Wildi LM; Exer P; Tamborrini G; Bernhard J; Möller B; Zufferey P; Nissen MJ; Scherer A; Ciurea A;
Arthritis Res Ther; 2017 Jul; 19(1):164. PubMed ID: 28724442
[TBL] [Abstract][Full Text] [Related]
24. Selecting patients with ankylosing spondylitis for TNF inhibitor therapy: comparison of ASDAS and BASDAI eligibility criteria.
Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Kalstad S; Kvien TK
Rheumatology (Oxford); 2012 Aug; 51(8):1479-83. PubMed ID: 22499062
[TBL] [Abstract][Full Text] [Related]
25. Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis.
Gratacós J; Pontes C; Juanola X; Sanz J; Torres F; Avendaño C; Vallano A; Calvo G; de Miguel E; Sanmartí R;
Arthritis Res Ther; 2019 Jan; 21(1):11. PubMed ID: 30621746
[TBL] [Abstract][Full Text] [Related]
26. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
[TBL] [Abstract][Full Text] [Related]
27. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
29. Comparing Tapering Strategy to Standard Dosing Regimen of Tumor Necrosis Factor Inhibitors in Patients with Spondyloarthritis in Low Disease Activity.
Plasencia C; Kneepkens EL; Wolbink G; Krieckaert CL; Turk S; Navarro-Compán V; L'Ami M; Nurmohamed MT; van der Horst-Bruinsma I; Jurado T; Diego C; Bonilla G; Villalba A; Peiteado D; Nuño L; van der Kleij D; Rispens T; Martín-Mola E; Balsa A; Pascual-Salcedo D
J Rheumatol; 2015 Sep; 42(9):1638-46. PubMed ID: 26178279
[TBL] [Abstract][Full Text] [Related]
30. Treatment of ankylosing spondylitis with TNF inhibitors does not have adverse effect on results of liver function tests: a longitudinal study.
Capkin E; Karkucak M; Cosar AM; Ak E; Karaca A; Gokmen F; Budak BS; Tosun M
Int J Rheum Dis; 2015 Jun; 18(5):548-52. PubMed ID: 24612551
[TBL] [Abstract][Full Text] [Related]
31. Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.
Michielsens CAJ; Boers N; den Broeder N; Wenink MH; van der Maas A; Mahler EAM; Mulder MLM; van der Heijde D; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Trials; 2020 Jan; 21(1):90. PubMed ID: 31941544
[TBL] [Abstract][Full Text] [Related]
32. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
[TBL] [Abstract][Full Text] [Related]
34. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
35. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
[TBL] [Abstract][Full Text] [Related]
36. Risk of disease flare in spondyloarthritis patients after tapering tumor necrosis factor inhibitors: A meta-analysis and literature review.
Min HK; Kim HR; Lee SH; Nam B; Shin JH; Kim TH
Int Immunopharmacol; 2024 Jun; 134():112167. PubMed ID: 38754279
[TBL] [Abstract][Full Text] [Related]
37. Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR.
Maksymowych WP; Claudepierre P; de Hooge M; Lambert RG; Landewé R; Molto A; van der Heijde D; Bukowski JF; Jones H; Pedersen R; Szumski A; Vlahos B; Dougados M
Arthritis Res Ther; 2021 Jan; 23(1):43. PubMed ID: 33514428
[TBL] [Abstract][Full Text] [Related]
38. Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO.
Llop M; Moreno M; Navarro-Compán V; Juanola X; de Miguel E; Almodóvar R; Quintana EC; Sanz JS; Beltrán E; Montesinos MDR; Calvet J; Berenguer-Llergo A; Gratacós J;
Arthritis Res Ther; 2022 Jan; 24(1):30. PubMed ID: 35063018
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.
Türk SM; Öztürk Z; Karataş D; Erkorkmaz Ü; Gönüllü E
Turk J Med Sci; 2022 Apr; 52(2):522-523. PubMed ID: 36161620
[TBL] [Abstract][Full Text] [Related]
40. Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.
Jeong H; Eun YH; Kim IY; Kim H; Ahn JK; Lee J; Koh EM; Cha HS
Korean J Intern Med; 2018 Mar; 33(2):407-416. PubMed ID: 27729625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
